Kezar Life Sciences, Inc.KZR
Market cap
$45.73M
P/E ratio
| Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Collaboration revenue | - | - | - | - | - | 7 | - |
| Research and development | 18 | 27 | 31 | 39 | 51 | 86 | 66 |
| General and administrative | 7 | 10 | 12 | 16 | 20 | 27 | 23 |
| Restructuring and impairment charges | - | - | - | - | - | 6 | 1 |
| Total operating expenses | 25 | 37 | 43 | 55 | 71 | 118 | 91 |
| Loss from operations | -25 | -37 | -43 | -55 | -71 | -111 | -91 |
| Interest income | - | - | - | - | - | - | 8 |
| Interest expense | - | - | - | - | - | - | 2 |
| Net loss | -23 | -35 | -42 | -55 | -68 | -102 | -84 |
| Earnings Per Share, Basic | - | - | - | - | -1.01 | -1.4 | -11.49 |
| Earnings Per Share, Diluted | - | - | - | - | -1.01 | -1.4 | -11.49 |